BAY 57-1293 for cell activation

BAY 57-1293 is a potent helicase primase inhibitor. It inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. BAY 57-1293 has been shown to be a more effective agent than acyclovir (Cat. No. 2200) for treating Alzjeimer’s Disease (AD) by decreasing Aβ and P-tau formation.

N/A

348086-71-5

402.49

Biochemicals

N-methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide

C₁₈H₁₈N₄O₃S₂

White to off-white solid

N/A

No

Yes

≥95% by HPLC

DMSO

-20°C

Gel pack

24 months

Protect from air and light

cell

For cells, cell lines and tissues in culture till half confluency.